Drug Trial Radar · NCT03778229
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
367
Actual
Start
Jan 9, 2019
Primary completion
Aug 23, 2024
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Hutchison Medipharma Limited
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in participants with epidermal growth factor receptor mutation positive (EGFRm+) and mesenchymal epithelial transition factor positive (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following treatment with osimertinib.
Conditions
- Carcinoma
Interventions
OsimertinibDrug
Participants will receive oral osimertinib tablets as stated in the arm descripation.
SavolitinibDrug
Participants will receive oral savolitinib tablets as stated in the arm descripation.
PlaceboDrug
Participants will receive oral placebo tablets as stated in the arm descripation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis SetTime frame: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years
- Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis SetTime frame: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years
Locations
90 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Sacramento, California
Research Site
Washington D.C., District of Columbia
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Rochester, Minnesota
Research Site
Brooklyn, New York
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Seattle, Washington
Research Site
Barretos, Brazil
Research Site
Curitiba, Brazil
Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Santiago, Chile
Research Site
Santiago, Chile
Research Site
Santiago, Chile
Research Site
Aalborg, Denmark
Research Site
Herlev, Denmark
Research Site
København Ø, Denmark
Research Site
Næstved, Denmark
Research Site
Odense, Denmark
Research Site
Vejle, Denmark
Research Site
Dijon, France
Research Site
Marseille, France
Research Site
Nantes, France
Research Site
Paris, France
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.